Home › Linfoma diffuso a grandi cellule B › Texas › Houston
Studi clinici su Linfoma diffuso a grandi cellule B a Houston, TX
17 studi su Linfoma diffuso a grandi cellule B cercano partecipanti presso sedi a Houston e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
In reclutamentoFase 2
- MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
In reclutamentoStudio osservazionale
- Texas Children's Hospital, Houston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
In reclutamentoFase 1/2
- Md Anderson Cancer Center, Houston
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
In reclutamentoFase 3
- Houston Methodist Cancer Center ( Site 0154), Houston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
In reclutamentoFase 1
- Baylor College of Medicine, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
In reclutamentoFase 1
- MD Anderson Cancer Center, Houston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
In reclutamentoFase 1/2
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
In reclutamentoFase 1
- Md Anderson Cancer Center, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
In reclutamentoFase 1/2
- MD Anderson Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
In reclutamentoFase 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
In reclutamentoFase 3
- MD Anderson Cancer Center, Houston
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
In reclutamentoFase 1
- The University of TX MD Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
In reclutamentoFase 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
In reclutamentoFase 1
- MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
In reclutamentoFase 1
- MD Anderson Cancer Center, Houston
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
In reclutamentoFase 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Study of NX-1607 in Adults With Advanced Malignancies
In reclutamentoFase 1
- MD Anderson Cancer Center, Houston
Studi su Linfoma diffuso a grandi cellule B in altre città
- New York City, NY21 studi
- Baldwin Park, CA19 studi
- Chicago, IL18 studi
- Los Angeles, CA17 studi
- Boston, MA16 studi
- Milwaukee, WI16 studi
- Portland, OR15 studi
- Nashville, TN15 studi
- Philadelphia, PA15 studi
- Durham, NC14 studi
- Dallas, TX13 studi
- Seattle, WA12 studi
Altri studi a Houston
- Cancro del polmone non a piccole cellule145 studi
- Cancro al seno126 studi
- Cancro (tutti i tipi)121 studi
- Cancro metastatico104 studi
- Cancro colorettale102 studi
- Cancro ovarico89 studi
- Leucemia mieloide acuta85 studi
- Cancro ai polmoni78 studi
- Cancro alla prostata76 studi
- Cancro dell'endometrio68 studi
- Cancro pancreatico61 studi
- Melanoma59 studi
Fonte: ClinicalTrials.gov, dati recuperati il 3 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.